{"pmid":32353251,"pmcid":"PMC7185942","title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation.","text":["COVID-19 cytokine storm: the interplay between inflammation and coagulation.","Lancet Respir Med","Jose, Ricardo J","Manuel, Ari","32353251"],"journal":"Lancet Respir Med","authors":["Jose, Ricardo J","Manuel, Ari"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353251","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/S2213-2600(20)30216-2","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495639355394,"score":9.490897,"similar":[{"pmid":32384917,"title":"COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.","text":["COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.","Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presently become a rapidly spreading and devastating global pandemic. Veno-venous extracorporeal membrane oxygenation (V-V ECMO) may serve as life-saving rescue therapy for refractory respiratory failure in the setting of acute respiratory compromise such as that induced by SARS-CoV-2. While still little is known on the true efficacy of ECMO in this setting, the natural resemblance of seasonal influenza's characteristics with respect to acute onset, initial symptoms, and some complications prompt to ECMO implantation in most severe, pulmonary decompensated patients. The present review summarizes the evidence on ECMO management of severe ARDS in light of recent COVID-19 pandemic, at the same time focusing on differences and similarities between SARS-CoV-2 and ECMO in terms of hematological and inflammatory interplay when these two settings merge.","Crit Care","Kowalewski, Mariusz","Fina, Dario","Slomka, Artur","Raffa, Giuseppe Maria","Martucci, Gennaro","Lo Coco, Valeria","De Piero, Maria Elena","Ranucci, Marco","Suwalski, Piotr","Lorusso, Roberto","32384917"],"abstract":["Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presently become a rapidly spreading and devastating global pandemic. Veno-venous extracorporeal membrane oxygenation (V-V ECMO) may serve as life-saving rescue therapy for refractory respiratory failure in the setting of acute respiratory compromise such as that induced by SARS-CoV-2. While still little is known on the true efficacy of ECMO in this setting, the natural resemblance of seasonal influenza's characteristics with respect to acute onset, initial symptoms, and some complications prompt to ECMO implantation in most severe, pulmonary decompensated patients. The present review summarizes the evidence on ECMO management of severe ARDS in light of recent COVID-19 pandemic, at the same time focusing on differences and similarities between SARS-CoV-2 and ECMO in terms of hematological and inflammatory interplay when these two settings merge."],"journal":"Crit Care","authors":["Kowalewski, Mariusz","Fina, Dario","Slomka, Artur","Raffa, Giuseppe Maria","Martucci, Gennaro","Lo Coco, Valeria","De Piero, Maria Elena","Ranucci, Marco","Suwalski, Piotr","Lorusso, Roberto"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32384917","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1186/s13054-020-02925-3","locations":["Veno"],"topics":["Treatment"],"weight":1,"_version_":1666340102006112258,"score":72.71686},{"pmid":32428809,"title":"Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.","text":["Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role.","Med Hypotheses","Magro, Giuseppe","32428809"],"journal":"Med Hypotheses","authors":["Magro, Giuseppe"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428809","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.mehy.2020.109829","keywords":["covid-19","coagulation","coagulation disorder","coagulopathy","cytokine storm","cytokines","heparin","lmwh","sars-cov-2"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728912789506,"score":60.045296},{"pmid":32412405,"title":"Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.","text":["Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.","Eur J Rheumatol","Miossec, Pierre","32412405"],"journal":"Eur J Rheumatol","authors":["Miossec, Pierre"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412405","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5152/eurjrheum.2020.2062","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666897319061094401,"score":59.258945},{"pmid":32385712,"title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","text":["Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.","Cancer Metastasis Rev","Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D","32385712"],"abstract":["Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19."],"journal":"Cancer Metastasis Rev","authors":["Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385712","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10555-020-09889-4","keywords":["covid-19","cytokine storms","eicosanoid storm","inflammation resolution","sars-cov-2"],"e_drugs":["Eicosanoids","Arachidonic Acid","Lipids","Prostaglandins","Leukotrienes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102065881089,"score":57.235523},{"pmid":32283152,"pmcid":"PMC7194613","title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","text":["The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.","Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.","J Infect","Ye, Qing","Wang, Bili","Mao, Jianhua","32283152"],"abstract":["Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment."],"journal":"J Infect","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283152","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.037","keywords":["2019-ncov","coronavirus","cytokine storm","immunomodulation","sars-cov-2"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491454488580,"score":47.96927}]}